BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Caviglia R, Boškoski I, Cicala M. Long-term treatment with infliximab in inflammatory bowel disease: safety and tolerability issues. Expert Opinion on Drug Safety 2008;7:617-32. [DOI: 10.1517/14740338.7.5.617] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
Number Citing Articles
1 Denmark VK, Mayer L. Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease: an update. Expert Review of Clinical Immunology 2014;9:77-92. [DOI: 10.1586/eci.12.91] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
2 Chen C, Liu F. Research progress in genetic animal models of inflammatory bowel disease. Shijie Huaren Xiaohua Zazhi 2008; 16(34): 3870-3876 [DOI: 10.11569/wcjd.v16.i34.3870] [Reference Citation Analysis]
3 Sena A, Grishina I, Thai A, Goulart L, Macal M, Fenton A, Li J, Prindiville T, Oliani SM, Dandekar S, Goulart L, Sankaran-Walters S. Dysregulation of anti-inflammatory annexin A1 expression in progressive Crohns Disease. PLoS One 2013;8:e76969. [PMID: 24130820 DOI: 10.1371/journal.pone.0076969] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 3.3] [Reference Citation Analysis]
4 Yamashiro Y, Martin J, Gazarian M, Kling S, Nakamura H, Matsui A, Cucchiara S, Aloi M, Wynn EL, Mulberg AE. Drug Development: The Use of Unlicensed/Off-label Medicines in Pediatrics. Journal of Pediatric Gastroenterology & Nutrition 2012;55:506-10. [DOI: 10.1097/mpg.0b013e318272af1f] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Jin H, Guo J, Liu J, Lyu B, Foreman RD, Shi Z, Yin J, Chen JDZ. Autonomically mediated anti-inflammatory effects of electrical stimulation at acupoints in a rodent model of colonic inflammation. Neurogastroenterol Motil 2019;31:e13615. [PMID: 31117153 DOI: 10.1111/nmo.13615] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
6 Ramadass B, Chittaranjan S, Subramanian V, Ramakrishna BS. Fecal polymerase chain reaction for Mycobacterium tuberculosis IS6110 to distinguish Crohn's disease from intestinal tuberculosis. Indian J Gastroenterol. 2010;29:152-156. [PMID: 20577845 DOI: 10.1007/s12664-010-0022-3] [Cited by in Crossref: 26] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
7 de Boer S, Wilsher M. Review series: Aspects of interstitial lung disease. Sarcoidosis. Chron Respir Dis 2010;7:247-58. [PMID: 21084549 DOI: 10.1177/1479972310388352] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
8 Magro F, Portela F. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies. BioDrugs. 2010;24 Suppl 1:3-14. [PMID: 21175228 DOI: 10.2165/11586290-000000000-00000] [Cited by in Crossref: 56] [Cited by in F6Publishing: 59] [Article Influence: 5.1] [Reference Citation Analysis]
9 Delasos L, Desai A, Lopetegui Lia N, Kethireddy N, Ray C. A Case of Immunotherapy-Induced Colitis Complicated by Perforation and Treated with Infliximab Postoperatively. Case Rep Oncol Med 2019;2019:9069354. [PMID: 31428491 DOI: 10.1155/2019/9069354] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
10 Gordon JP, McEwan PC, Maguire A, Sugrue DM, Puelles J. Characterizing unmet medical need and the potential role of new biologic treatment options in patients with ulcerative colitis and Crohn's disease: a systematic review and clinician surveys. Eur J Gastroenterol Hepatol 2015;27:804-12. [PMID: 25933126 DOI: 10.1097/MEG.0000000000000378] [Cited by in Crossref: 18] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
11 Shah B, Mayer L. Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease. Expert Rev Clin Immunol 2010;6:607-20. [PMID: 20594134 DOI: 10.1586/eci.10.45] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
12 Sankaran-Walters S, Ransibrahmanakul K, Grishina I, Hung J, Martinez E, Prindiville T, Dandekar S. Epstein-Barr virus replication linked to B cell proliferation in inflamed areas of colonic mucosa of patients with inflammatory bowel disease. J Clin Virol. 2011;50:31-36. [PMID: 21035384 DOI: 10.1016/j.jcv.2010.09.011] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
13 Yorulmaz E, Sezgin A, Yorulmaz H, Adali G, Ciftci H. Prolonged QT dispersion in inflammatory bowel disease. World J Gastroenterol 2013; 19(1): 65-71 [PMID: 23326164 DOI: 10.3748/wjg.v19.i1.65] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
14 Tomáš Ľ, Lazúrová I, Pundová L, Oetterová M, Zakuciová M, Petrášová D, Studenčan M. Acute and long-term effect of infliximab on humoral and echocardiographic parameters in patients with chronic inflammatory diseases. Clin Rheumatol 2013;32:61-6. [DOI: 10.1007/s10067-012-2091-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
15 Gronbach K, Eberle U, Müller M, Olschläger TA, Dobrindt U, Leithäuser F, Niess JH, Döring G, Reimann J, Autenrieth IB, Frick JS. Safety of probiotic Escherichia coli strain Nissle 1917 depends on intestinal microbiota and adaptive immunity of the host. Infect Immun 2010;78:3036-46. [PMID: 20421387 DOI: 10.1128/IAI.00218-10] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
16 Curione M, Aratari A, Amato S, Colotto M, Barbato M, Leone S, Tego A, Panetti D, Parlapiano C. A study on QT interval in patients affected with inflammatory bowel disease without cardiac involvement. Intern Emerg Med. 2010;5:307-310. [PMID: 20411364 DOI: 10.1007/s11739-010-0382-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
17 Stratton R, Slapak G, Mahungu T, Kinloch-de Loes S. Autoimmunity and HIV. Curr Opin Infect Dis 2009;22:49-56. [PMID: 19532080 DOI: 10.1097/QCO.0b013e3283210006] [Cited by in Crossref: 31] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
18 de la Poza Gómez G, López-san Román A, Masjuan Vallejo J, Arranz de la Mata G, Angueira Lapeña T, Boixeda de Miquel D. Colitis ulcerosa asociada a enfermedad de Vogt-Koyanagi-Harada. Gastroenterología y Hepatología 2009;32:343-5. [DOI: 10.1016/j.gastrohep.2008.11.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
19 Pollastri MP, Whitty A, Merrill JC, Tang X, Ashton TD, Amar S. Identification and characterization of kava-derived compounds mediating TNF-alpha suppression. Chem Biol Drug Des 2009;74:121-8. [PMID: 19538508 DOI: 10.1111/j.1747-0285.2009.00838.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
20 Chiappini E, de Martino M, Mangiantini F, Lionetti P. Crohn disease and mycobacterial infection in children: an intriguing relationship. J Pediatr Gastroenterol Nutr. 2009;49:550-558. [PMID: 19680150 DOI: 10.1097/mpg.0b013e3181b0f908] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
21 Maev IV, Kazulin AN, Andreev DN. The cardiovascular system in patients with functional and inflammatory bowel diseases. Ter Arkh 2018;90:59-64. [PMID: 30701774 DOI: 10.26442/terarkh201890259-64] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
22 Jin H, Guo J, Liu J, Lyu B, Foreman RD, Yin J, Shi Z, Chen JDZ. Anti-inflammatory effects and mechanisms of vagal nerve stimulation combined with electroacupuncture in a rodent model of TNBS-induced colitis. American Journal of Physiology-Gastrointestinal and Liver Physiology 2017;313:G192-202. [DOI: 10.1152/ajpgi.00254.2016] [Cited by in Crossref: 53] [Cited by in F6Publishing: 51] [Article Influence: 10.6] [Reference Citation Analysis]
23 Eshuis EJ, Bemelman WA, Stokkers PC. Infliximab for the treatment of ulcerative colitis. Expert Review of Gastroenterology & Hepatology 2014;3:219-29. [DOI: 10.1586/egh.09.19] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
24 Loftus EV, Colombel J, Schreiber S, Randall CW, Regueiro M, Ali T, Arendt C, Coarse J, Spearman M, Kosutic G. Safety of Long-term Treatment With Certolizumab Pegol in Patients With Crohn's Disease, Based on a Pooled Analysis of Data From Clinical Trials. Clinical Gastroenterology and Hepatology 2016;14:1753-62. [DOI: 10.1016/j.cgh.2016.07.019] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
25 Caviglia R, Boskoski I, Cicala M. Maintenance treatment with infliximab for the management of Crohn's disease in adults. Biologics 2009;3:39-49. [PMID: 19707394 DOI: 10.2147/btt.2009.2763] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
26 Wee XT, Koh Y, Yap CW. Automated systems to identify relevant documents in product risk management. BMC Med Inform Decis Mak 2012;12:13. [PMID: 22380483 DOI: 10.1186/1472-6947-12-13] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
27 Bagul A. Ischaemic/reperfusion injury: Role of infliximab. World J Transplant 2012; 2(3): 35-40 [PMID: 24175194 DOI: 10.5500/wjt.v2.i3.35] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]